Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Kanada2. fázis

This Study is Comparing Morning vs Random Scheduling of Standard of Care Pembrolizumab Checkpoint Inhibitor Immunotherapy Infusions in Patients With Metastatic Non-small Cell Lung Cancer

A legfontosabb adatok

Ki végzi
AHS Cancer Control Alberta
Hol
Edmonton (Kanada)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
58 fő, tervezett
Kezdés
2026. aug. 31.
Várható befejezés
2028. júl.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Scheduling of the time of pembrolizumab infusions
A regiszteradat frissítve
2026. november 5.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

A vizsgálat olyan felnőtteket keres, akiknek áttétes nem kissejtes tüdőrákjuk van, és pembrolizumab kezelést kapnak. A reggeli infúziókat hasonlítja össze a véletlenszerű időpontú infúziókkal.

Életkor
18 éves vagy idősebb
Nem
Bármely nem részt vehet
A betegség stádiuma
Áttétes nem kissejtes tüdőrák, szövettanilag igazolva, ECOG általános állapot 0-2
Korábbi kezelés
Kaphatnia kell a szokásos ellátásban alkalmazott pembrolizumabot. Nem kaphat egyidejűleg más szisztémás kezelést, és a kezelési terv nem tartalmazhat sugárkezelést vagy műtétet.
Biomarker vagy leletérték
PDL1 festődés 50% vagy több a szokásos ellátás szerinti IHC vizsgálaton

A részvétel fő kizáró okai

  • A pembrolizumab mellett más szisztémás kezelés
  • A kezelési terv sugárkezelést vagy műtétet tartalmaz
  • Kezeletlen, tüneteket okozó agyi áttét, vagy kortikoszteroidot igénylő agyi áttét
  • Leptomeningeális betegség
  • Ismert HIV-fertőzés, aktív hepatitis B vagy hepatitis C

A regiszter feltételei, szó szerint

Mind a 21 feltétel megnézéseKevesebb

Ki vehet részt

  • Patients with histologic diagnosis mNSCLC with PDL1 staining ≥ 50% on standard of care IHC testing
  • Patients must be eligible for treatment with standard-of-care pembrolizumab
  • Patients must be 18 years of age or older
  • Patients must be capable of providing consent to enrolment and willing to comply with study, treatment and follow-up
  • Patients with a performance status of Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Oken et al., 1982) will be eligible for enrolment
  • Women of childbearing potential (WOCBP) must have a negative serum (or urine) pregnancy test within 7 days prior to the first dose of pembrolizumab. WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy or bilateral salpingectomy) and is not postmenopausal. Menopause is defined as 12 months of amenorrhea in a woman over age 45 years in the absence of other biological or physiological causes
  • Patients of childbearing / reproductive potential should use adequate birth control methods, as defined by the investigator, during the study treatment period. A highly effective method of birth control is defined as those that result in low failure rate (i.e. less than 1% per year) when used consistently and correctly; Note: abstinence is acceptable if this is established and preferred contraception for the patient and is accepted as a local standard
  • Absence of any condition hampering compliance with the study protocol and follow- up schedule; those conditions should be discussed with the patient before registration in the trial
  • The following adequate organ function laboratory values must be met:; Hematological:
  • Absolute neutrophil count (ANC) >1.0
  • Platelet count >100
  • Hemoglobin >90 mg/dL; Renal:; o Serum creatinine <3x upper limited of normal (ULN); Hepatic:
  • Total serum bilirubin <2x ULN
  • AST and ALT <3x ULN; Coagulation:; o International Normalized Ratio (INR) <1.5x ULN (unless patient is receiving anticoagulant therapy and if PT or PTT is within therapeutic range of intended use of anticoagulants)

Ki nem vehet részt

  • Concurrent therapy with systemic therapy other than pembrolizumab (such as chemotherapy, targeted therapy, other checkpoint inhibitors, or hormonal therapy)
  • Treatment plan includes local therapy such as radiation or surgery
  • Untreated symptomatic brain metastases, or previously treated brain metastases requiring corticosteroids for symptom control. Patients with untreated asymptomatic brain metastases, where all lesions are < 2cm in size with no vasogenic edema, are eligible
  • Presence of leptomeningeal disease
  • Known history of human immunodeficiency virus (HIV), active Hepatitis B or Hepatitis C. Testing for HIV, HBV or HCV is not mandatory for enrolment to study but may occur at the discretion of the investigator
  • Active autoimmune disease that has required systemic treatment in past 12 months (i.e. with use of disease modifying agents, requiring >10mg prednisone or equivalent or other immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment
  • Participant unwilling to agree to their treatment times being scheduled as per study protocol during the study treatment period (Cycles 1-6)

Helyszínek itt: Kanada

  • Cross Cancer InstituteEdmonton, KanadaContact: Matthew Anaka, MD, PhD, FRCPCRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

This clinical trial is comparing morning infusions of the study drug (pembrolizumab) to random infusion scheduling for patients with non-small cell lung cancer.

A teljes eredeti leírásKevesebb

Participants will be randomized to either the Intervention (Morning Group) where Infusion start times are restricted between 0800 AM and 1000 AM or to the Control (Standard of Care) group where scheduling will occur as standard of care scheduling, in which infusions are scheduled without respect to a specific time of day.

There are past studies that suggest the timing of treatment may influence immune response and outcomes. This idea is called chronotherapy. Chronotherapy explores the notion that the timing of drug administration in relation to the body's internal clock can optimize treatment effectiveness. The timing of the infusions for the morning group was therefore, chosen based on data from these past studies that looked at circadian variation in immune system function with the intent to focus on similar infusion windows.

The aim of this study is to provide confirmation that the intervention is possible to achieve and use these results to design a larger study. Circadian timing of drug administration, if effective, would represent an intervention that could improve survival outcomes at no additional cost or apparent increase in toxicity, which is truly rare in oncology.

Participants are asked to participate in the study intervention for 18 weeks (6 cycles of pembrolizumab), after which participants would continue with ad hoc scheduling as per standard of care.

A vizsgálat 2 csoportja

  • Intervention (Morning Infusion)A vizsgált kezelés

    The intervention in this study is scheduling of the time of pembrolizumab infusions. This group will have their infusion start times restricted to between 0800 AM and 1000 AM .

    Kezelés: Scheduling of the time of pembrolizumab infusions

  • Standard of CareMár használt kezelés, összehasonlításként

    This group will undergo randomized scheduling in which infusions are scheduled without respect to a specific time of day. The start time of each infusion that will occur during the study intervention period will be randomized into 1 of 3 time periods: 1000 AM to 1200 PM, 1201 PM to 1400 PM, and 1401 PM to 1700 PM. Randomization of scheduling in the Standard of Care Group approximates the typical ad hoc scheduling of infusion times done as standard of care, with reduction in potential for bias on the part of those involved in scheduling given the unblinded nature of the intervention. The time windows for the Standard of Care group have been chosen to allow infusions to be scheduled throughout the day without overlap with the specific scheduling window of the Morning Group, in order to simplify interpretation of clinical outcomes.

    Kezelés: Scheduling of the time of pembrolizumab infusions

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Timing of Immunotherapy for the Modulation of Efficacy: a Pilot Study in Metastatic Non-Small Cell Lung Cancer
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 12.
A regiszteradat frissítve
2026. november 5.